TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05066529

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dry-needling
Description: Dry needling is a technique in which a fine needle is used to penetrate the skin, subcutaneous tissues and muscles to mechanically disrupt tissue without the use of anesthesia. Treatment is often used to treat myofascial trigger points.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: dry-needling
Description: Dry needling is a technique in which a fine needle is used to penetrate the skin, subcutaneous tissues and muscles to mechanically disrupt tissue without the use of anesthesia. Treatment is often used to treat myofascial trigger points.
Study: NCT06657404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: use Amiodarone, Bisoprolol and Digoxin
Description: Amiodarone 200mg tid orally for 1 week, then reduced to 200mg bid orally for another week.~The dose of amiodarone will be reduced to 200mg bid orally for 1 week, and then 200mg qd maintenance treatment will be started in the 3rd week of dosing.~Bisoprolol 2.5-5mg qd oral treatment, the specific dose is decided by the investigator.~Digoxin 0.125mg qd orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: use Amiodarone, Bisoprolol and Digoxin
Description: Amiodarone 200mg tid orally for 1 week, then reduced to 200mg bid orally for another week.~The dose of amiodarone will be reduced to 200mg bid orally for 1 week, and then 200mg qd maintenance treatment will be started in the 3rd week of dosing.~Bisoprolol 2.5-5mg qd oral treatment, the specific dose is decided by the investigator.~Digoxin 0.125mg qd orally.
Study: NCT06656676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WePrEP: A shared decision-making tool
Description: WePrEP will be bilingual, both patient- and provider-facing, stored on the provider's electronic device (and will have the capability to integrate with electronic health records in the future to enable scalability), and easily accessible during in-person or virtual patient-provider encounters. WePrEP is designed to present pertinent PrEP information to transgender women and their PrEP service providers to stimulate discussions about PrEP choice and support adherence (once a PrEP strategy has been chosen). We hypothesize that this will ensure selection of the ideal PrEP method and improve subsequent adherence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WePrEP: A shared decision-making tool
Description: WePrEP will be bilingual, both patient- and provider-facing, stored on the provider's electronic device (and will have the capability to integrate with electronic health records in the future to enable scalability), and easily accessible during in-person or virtual patient-provider encounters. WePrEP is designed to present pertinent PrEP information to transgender women and their PrEP service providers to stimulate discussions about PrEP choice and support adherence (once a PrEP strategy has been chosen). We hypothesize that this will ensure selection of the ideal PrEP method and improve subsequent adherence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: CDC recommendations for discussing PrEP
Description: Standard of care recommendations to discuss PrEP with potential end-users, endorsed by the CDC.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: CDC recommendations for discussing PrEP
Description: Standard of care recommendations to discuss PrEP with potential end-users, endorsed by the CDC.
Study: NCT06656806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Measure concentrations of CBD in spot urine collections from subjects treated with inhaled CBD
Description: Measure concentrations of CBD in spot urine collections from subjects with generalized anxiety disorder treated with inhaled CBD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Determine the presence and concentration of CBD in subject's plasma with inhaled CBD
Description: Determine the presence and concentration of CBD in plasma of subjects with generalized anxiety disorder treated with inhaled CBD
Study: NCT05783973

Intervention type: DIAGNOSTIC_TEST
Intervention: Next generation sequencing
Description: Extract DNA from bile，tissue and tissue sample, minimum DNA amount should be over 50ng.

Intervention type: DIAGNOSTIC_TEST
Intervention: Next generation sequencing
Description: Extract DNA from bile，tissue and tissue sample, minimum DNA amount should be over 50ng.

Intervention type: DIAGNOSTIC_TEST
Intervention: Next generation sequencing
Description: Extract DNA from bile，tissue and tissue sample, minimum DNA amount should be over 50ng.
Study: NCT06656962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telitacicept 160mg
Description: Telitacicept for Injection combined with standard therapy (Prednisone and Cyclophosphamide) for the treatment of ANCA-associated nephritis (AAGN).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone (and methylprednisolone)
Description: Methylprednisone shock therapy (500mg, 3 times), followed by Prednisone (1 mg·kg·d and a pre-determined tapering guideline \[PEXIVAS regimen\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide, intravenous injection, once every 2 to 3 weeks, 0.75 g/m² each time, the maximum cumulative dose of 8g
Study: NCT06657144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHS-114
Description: Sterile solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHS-114
Description: Sterile solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Sterile solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Sterile solution for infusion
Study: NCT06656871

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: iron supplementation
Description: The iron tablet group received iron supplementation (30 mg, 1 tablet/day of iron) for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Biostimulated lettuce supplementation
Description: the intervention group SwE lettuce group received lettuce biostimulated with Ecklonia Maxima algae (SwE lettuce, 100 grams/day) daily for 4 weeks
Study: NCT06656728

Intervention type: OTHER
Intervention: Blood-based liquid biopsy
Description: Venous blood sample will be taken from the patient as part of the routine blood tests taken as part of the work at the Medical Center
Study: NCT06655922

Intervention type: DIAGNOSTIC_TEST
Intervention: FAPI Imaging
Description: Studies have shown that imaging with radionuclide-labeled fibroblast activation protein inhibitor (FAPI) is a reliable technique for detecting myocardial fibrosis and activated CFs in arteries. Preliminary evidence suggests that FAPI imaging can assess plaque characteristics and the status of myocardial fibrosis in various cardiovascular diseases.
Study: NCT06657287

Intervention type: OTHER
Intervention: Mixed meal test
Description: The biochemical parameters, blood pressure, and heart rates of participants undergoing the mixed meal test will be recorded over a 5-hour period.
Study: NCT06617481

Intervention type: DRUG
Group type: OTHER
Intervention: 18F-rhPSMA-7.3 (Posluma)
Description: PET Scan using Posluma for detection of early recurrence of prostate cancer.
Study: NCT04714671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The virtual version of the Social stress task : V-TSST
Description: The task consists in a brief presentation about the abilities of participants followed by an arithmetic task in front of a virtual 3D audience projected and one researcher in a small room.First, participants have 5 minutes to prepare an exhibition about their qualities, their strengths and defects, and, why they identify with them. During this period virtual reality shows a closed curtain, and sounds from the audience can be heard. In the second phase, the curtain is raised and the participant must expose his speech during 5 minutes. Audience will remain attentive during 2 minutes, then audience will change to a restless attitude. The third phase consists of subtracting back a two-digit number from a four-digit number, as quickly as possible, starting again if participant makes a mistake. A debriefing of the test is scheduled at the end of the protocol, to remind patients of the purely fictional nature of this test. The visit will only end after a return to the baseline emotional state

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The virtual version of the Social stress task : V-TSST
Description: The task consists in a brief presentation about the abilities of participants followed by an arithmetic task in front of a virtual 3D audience projected and one researcher in a small room.First, participants have 5 minutes to prepare an exhibition about their qualities, their strengths and defects, and, why they identify with them. During this period virtual reality shows a closed curtain, and sounds from the audience can be heard. In the second phase, the curtain is raised and the participant must expose his speech during 5 minutes. Audience will remain attentive during 2 minutes, then audience will change to a restless attitude. The third phase consists of subtracting back a two-digit number from a four-digit number, as quickly as possible, starting again if participant makes a mistake. A debriefing of the test is scheduled at the end of the protocol, to remind patients of the purely fictional nature of this test. The visit will only end after a return to the baseline emotional state
Study: NCT05436249

Intervention type: DEVICE
Group type: OTHER
Intervention: Neurofeedback treatment
Description: During the fMRI scan, the tasks consist of:~1. Overt finger tapping in time with a flashing cue.~2. Motor imagery (of finger tapping).~During overt finger tapping, feedback will consist of a slider bar that indicates tapping accuracy to target speed (1 or 4Hz). During motor imagery, neurofeedback will consist of a slider bar that indicates the success of recruiting predicted brain regions (consistent with those engaged during overt tapping).
Study: NCT04866108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fruquintinib plus capecitabine
Description: oral fruquintinib plus capecitabine
Study: NCT04525092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Online Pre-dilution Hemodiafiltration
Description: The following parameters: maximum Blood flow rate allowed by vascular access, dialyste rate of 500 mL/min and average convective volume of \>44L/session reinjected in pre-dilution mode. The dialysate composition, net ultrafiltration rate and use of anticoagulation will be prescribed according to participant's characteristics.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Hemodialysis
Description: Using the following parameters: maximum Blood flow rate allowed by vascular access, dialysate rate of 500 mL/min, no convection. The dialysate composition, net ultrafiltration rate and use of anticoagulation will be prescribed according to participant's characteristics.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Online Post-dilution Hemodiafiltration
Description: The following parameters: maximum Blood flow rate allowed by vascular access, dialyste rate of 500 mL/min and average convective volume of \>22L/session reinjected in pre-dilution mode. The dialysate composition and net ultrafiltration rate will be prescribed according to participant's characteristics. Usage of intra-dialysis anticoagulation is mandatory.
Study: NCT05436249

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: At-home therapy
Description: Participants are assigned to groups where they will practice each day for 3 weeks at-home.~1. Group 1: Imagery only.~2. Group 2: Overt finger tapping only.~3. Group 3: Imagery plus overt finger tapping.~During imagery, participants will view the task while imagining that they are finger tapping in time with the flashing cue, using the imagery strategies identified during their previous neurofeedback session. During overt tapping, participants will finger tap in time with the flashing cue. A final assessment of overt tapping will be performed the day after therapy ends.
Study: NCT04730518

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga-based group therapy
Description: see above

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga-based group therapy
Description: see above
Study: NCT05928806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: Botensilimab 75mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Balstilimab 450mg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Ipilimumab 1mg/kg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab at induction: 3mg/kg IV Nivolumab at maintenance: 480mg IV
Study: NCT05142709

Intervention type: DRUG
Intervention: Anti-PD-1 Immune Checkpoint Inhibitors
Description: used as 1st line treatment for metastatic ESCC.
Study: NCT05646056

Intervention type: DEVICE
Intervention: Software
Description: Observation only

Intervention type: DEVICE
Intervention: Software
Description: Observation only

Intervention type: DEVICE
Intervention: Software
Description: Observation only

Intervention type: DEVICE
Intervention: Software
Description: Observation only
Study: NCT05180786

Intervention type: OTHER
Group type: OTHER
Intervention: Error Fields
Description: Participants will complete a reaching experiment using the robotic arm with error fields turned on.

Intervention type: OTHER
Group type: OTHER
Intervention: Error Fields
Description: Participants will complete a reaching experiment using the robotic arm with error fields turned on.

Intervention type: OTHER
Group type: OTHER
Intervention: No Error Fields
Description: Participants will complete a reaching experiment using the robotic arm with error fields turned off.

Intervention type: OTHER
Group type: OTHER
Intervention: No Error Fields
Description: Participants will complete a reaching experiment using the robotic arm with error fields turned off.
Study: NCT06090071

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LaseMD Laser
Description: The non-ablative fractional 1,927nm Thulium laser will be used in this study. This FDA-approved laser is an innovative device addressing as well as medical as aesthetic and cosmetic indications. The system allows nearly pain free treatments with depth of 200 μm setting multiple microbeams. The stratum corneum stays intact despite superficial ruptures, coagulation zones appear only in the underlying layers of the skin.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: LaseMD Laser
Description: The non-ablative fractional 1,927nm Thulium laser will be used in this study. This FDA-approved laser is an innovative device addressing as well as medical as aesthetic and cosmetic indications. The system allows nearly pain free treatments with depth of 200 μm setting multiple microbeams. The stratum corneum stays intact despite superficial ruptures, coagulation zones appear only in the underlying layers of the skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sciton Laser
Description: The Sciton Laser uses Broadband light (BBL), also known as intense pulse light, a commonly available and popular treatment to rejuvenate the skin. BBL uses a broad band of noncoherent light waves, ranging from 560 to 1,200 nm, that are absorbed by a number of components in the skin, leading to a reduction in dyschromia, background erythema, telangiectasia, and an increase in collagen production resulting in amelioration of fine lines.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sciton Laser
Description: The Sciton Laser uses Broadband light (BBL), also known as intense pulse light, a commonly available and popular treatment to rejuvenate the skin. BBL uses a broad band of noncoherent light waves, ranging from 560 to 1,200 nm, that are absorbed by a number of components in the skin, leading to a reduction in dyschromia, background erythema, telangiectasia, and an increase in collagen production resulting in amelioration of fine lines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phyto A+ Brightening Treatment
Description: Phyto A+ Brightening Treatment is a serum comprised of a soothing botanical blend matched with a keratolytic (3% azeleic acid), 2.5% niacinamide, a brightening compound (2 % α-arbutin), and botanical extracts

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phyto A+ Brightening Treatment
Description: Phyto A+ Brightening Treatment is a serum comprised of a soothing botanical blend matched with a keratolytic (3% azeleic acid), 2.5% niacinamide, a brightening compound (2 % α-arbutin), and botanical extracts
Study: NCT05177796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT05984745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 Forte® capsules
Description: Coenzyme Q10 in the form of soft gelatin capsules, each capsule containing 100 mg
Study: NCT04837014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prescription for regular acetaminophen and naproxen
Description: Patient allocated to the intervention arm will be discharged home with a prescription for regular acetaminophen and naproxen for 48 hours, and then prn for one week's duration. No narcotic will be prescribed at discharge post-operatively.
Study: NCT06224049

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hNeo-T
Description: After subject screening, peripheral blood mononuclear cell （PBMC） donors matching half or more of the subject's HLA matching will undergo blood collection to prepare hNeo-T. hNeo-T preparation is expected to be 25-30 days after blood collection. In this study, the bridging therapy will be allowed before Chemotherapy preconditioning, and the investigators will decide whether to use it. Chemotherapy preconditioning will be performed before hNeo-T transfusion. If the absolute value of lymphocyte (LYM) before pretreatment is \<0.8×10\^9/L and the subject meets the criteria for cell transfusion, the chemotherapy preconditioning will not be performed and subsequent cell transfusion can be performed directly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy preconditioning will be performed before hNeo-T transfusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy preconditioning will be performed before hNeo-T transfusion
Study: NCT04837014

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: prescription for regular acetaminophen , naproxen and dilaudid
Description: prescription for regular acetaminophen , naproxen and dilaudid
Study: NCT05319470

Intervention type: DIAGNOSTIC_TEST
Intervention: Intraocular pressure (IOP)
Description: Measurement of intraocular pressure in both eyes of the study population using the Goldman applanation tonometer.

Intervention type: DIAGNOSTIC_TEST
Intervention: Tear Break-up Time (TBUT)
Description: TBUT will be calculated after instillation of a drop of fluorescein dye, by slit lamp biomicroscopy.

Intervention type: DIAGNOSTIC_TEST
Intervention: Conjuctival Hyperemia
Description: Conjunctival hyperemia will be assessed by slit lamp biomicroscopy using a validated grading system.

Intervention type: DIAGNOSTIC_TEST
Intervention: Schirmer Test
Description: Schirmer test will be performed on both eyes to asses tear production.

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Fields and OCT RNFL
Description: Visual field examination using a Humphrey perimeter and measurement of peripapillary retinal nerve fiber layer thickness with optical coherence tomography.
Study: NCT06387316

Intervention type: OTHER
Group type: OTHER
Intervention: No Oral Stimulation
Description: No oral stimulation

Intervention type: OTHER
Group type: OTHER
Intervention: No Oral Stimulation
Description: No oral stimulation

Intervention type: OTHER
Group type: OTHER
Intervention: Oral water stimulation
Description: Oral water stimulation

Intervention type: OTHER
Group type: OTHER
Intervention: Oral Salt Stimulation
Description: Oral Salt Stimulation

Intervention type: OTHER
Group type: OTHER
Intervention: Oral Sucralose Stimulation
Description: Oral Sucralose Stimulation

Intervention type: OTHER
Group type: OTHER
Intervention: Oral Sucrose stimulation
Description: Oral Sucrose stimulation
Study: NCT06030180

Intervention type: DEVICE
Group type: OTHER
Intervention: EsoGuard
Description: EsoGuard is a set of genetic assays and algorithms for the assessment of specific methylation patterns of DNA encoding the genes vimentin (VIM) and cyclin A1 (CCNA1)
Study: NCT05723770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: instillation of NOV03
Description: This trial consists of 2 office visits over a period of approximately 2 weeks. At Visit 2, a designated clinical staff member or the investigator will instill 1 drop of NOV03 into each eye.
Study: NCT05163665

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closure type
Description: Patients will have their endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR) as per standard-of-care. Afterwards, patient will receive one of two intervention options for the closure of the GI defect following polyp removal.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure type
Description: Patients will have their endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR) as per standard-of-care. Afterwards, patient will receive one of two intervention options for the closure of the GI defect following polyp removal.
Study: NCT04844138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overcoming Anxiety in Pregnancy and Postpartum Online Self-Directed Program
Description: The investigators will administer the Overcoming Anxiety in Pregnancy and Postpartum program in an online self-directed format. This program is grounded in Cognitive Behavioural Therapy and will teach participants strategies to manage their anxiety. Participants will complete six modules that will be released to them on a bi-weekly basis.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Overcoming Anxiety in Pregnancy and Postpartum Online Self-Directed Program
Description: The investigators will administer the Overcoming Anxiety in Pregnancy and Postpartum program in an online self-directed format. This program is grounded in Cognitive Behavioural Therapy and will teach participants strategies to manage their anxiety. Participants will complete six modules that will be released to them on a bi-weekly basis.
Study: NCT05564117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide tablets orally once daily for 64 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo semaglutide
Description: Semaglutide placebo-matching tablets orally once daily for 64 weeks.